1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance [TA269] Published: 12 December 2012 Last updated: 01 January 2015

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Related NICE guidance
  • 7 Review of guidance
  • Appendix A: Appraisal Committee members, and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
Download guidance (PDF)

Guidance

  • Next

1 Guidance

1 Guidance

1.1 Vemurafenib is recommended as an option for treating BRAF V600 mutation‑positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)

  • Next